Keratitis in six dogs after topical treatment with carbonic anhydrase inhibitors for glaucoma

Journal of the American Veterinary Medical Association

Volumn 247, Issue 12, 2015, Pages 1419-1426

  Beckwith Cohen, Billie ^a,b   Bentley, Ellison ^a   Gasper, David J ^a   McLellan, Gillian J ^a   Dubielzig, Richard R ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; SULFONAMIDE; THIAZINE DERIVATIVE; THIOPHENE DERIVATIVE;

ANIMAL; CHEMICALLY INDUCED; DOG; DOG DISEASES; FEMALE; GLAUCOMA; KERATITIS; MALE; VETERINARY;

ANIMALS; CARBONIC ANHYDRASE INHIBITORS; DOG DISEASES; DOGS; FEMALE; GLAUCOMA; KERATITIS; MALE; SULFONAMIDES; THIAZINES; THIOPHENES;

EID: 84951808183     PISSN: 00031488     EISSN: 1943569X     Source Type: Journal    
DOI: 10.2460/javma.247.12.1419     Document Type: Article

References (34)

1. Willis AM, Diehl KA, Robbin TE. Advances in topical glaucoma therapy. Vet Ophthalmol 2002;5:9-17.
2. Dees DD, Fritz KJ, Maclaren NE, et al. Efficacy of prophylactic antiglaucoma and anti-inflammatory medications in canine primary angle-closure glaucoma: a multicenter retrospective study (2004-2012). Vet Ophthalmol 2014;17:195-200.
3. Nesher R, Ticho U. Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: effect on the quality of life of glaucoma patients with drug-related side effects. Isr Med Assoc J 2003;5:260-263.
4. Mincione F, Scozzafava A, Supuran CT. The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des 2008;14:649-654.
5. Gelatt KN, MacKay EO. Changes in intraocular pressure associated with topical dorzolamide and oral methazolamide in glaucomatous dogs. Vet Ophthalmol 2001;4:61-67.
6. Cawrse MA, Ward DA, Hendrix DV. Effects of topical application of a 2% solution of dorzolamide on intraocular pressure and aqueous humor flow rate in clinically normal dogs. Am J Vet Res 2001;62:859-863.
7. Morris S, Geh V, Nischal KK, et al. Topical dorzolamide and metabolic acidosis in a neonate. Br J Ophthalmol 2003;87:1052-1053.
8. Holdiness MR. Contact dermatitis to topical drugs for glaucoma. Am J Contact Dermat 2001;12:217-219.
9. Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary openangle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol 1998;126:400-408.
10. A topical carbonic anhydrase inhibitor for glaucoma. Med Lett Drugs Ther 1995;37:76-77.
11. Taguri AH, Khan MA, Sanders R. Marginal keratitis: an uncommon form of topical dorzolamide allergy. Am J Ophthalmol 2000;130:120-122.
12. Hegde V, Robinson R, Dean F, et al. Drug-induced ectropion: what is best practice? Ophthalmology 2007;114:362-366.
13. Konowal A, Morrison JC, Brown SV, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol 1999;127:403-406.
14. Munshi V, Ahluwalia H. Erythema multiforme after use of topical dorzolamide. J Ocul Pharmacol Ther 2008;24:91-93.
15. Martin XD, Danese M. Dorzolamide-induced immune thrombocytopenia: a case report and literature review. J Glaucoma 2001;10:133-135.
16. Santos VM, Castro RA, Lima CC, et al. Skin eruption and thrombocytopaenia in a woman with glaucoma: a case report. West Indian Med J 2010;59:102-105.
17. Mullins RJ, Lones R, Dutta B. Lichenoid drug eruption secondary to topical timolol and dorzolamide eye-drops. Australas J Dermatol 2004;45:151-152.
18. Kluger N, Guillot B, Raison-Peyron N. Systemic contact dermatitis to dorzolamide eye drops. Contact Dermat 2008;58:167-168.
19. Nagra PK, Rapuano CJ, Cohen EJ, et al. Thygeson's superficial punctate keratitis: ten years' experience. Ophthalmology 2004;111:34-37.
20. Holland EJ, Schwartz GS. Classification of herpes simplex virus keratitis. Cornea 1999;18:144-154.
21. Rosin LM, Bell NP. Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops. Clin Ophthalmol 2013;7:2131-2135.
22. Ledbetter EC, Kim SG, Dubovi EJ. Outbreak of ocular disease associated with naturally-acquired canine herpesvirus-1 infection in a closed domestic dog colony. Vet Ophthalmol 2009;12:242-247.
23. Coassin M, Lambiase A, Costa N, et al. Efficacy of topical nerve growth factor treatment in dogs affected by dry eye. Graefes Arch Clin Exp Ophthalmol 2005;243:151-155.
24. Andrew SE. Immune-mediated canine and feline keratitis. Vet Clin North Am Small Anim Pract 2008;38:269-290, vi.
25. Shedden A, Adamsons IA, Getson AJ, et al. Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT) in patients with elevated intraocular pressure in a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2010;248:1757-1764.
26. Stewart WC, Stewart JA, Nelson LA. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res 2011;36:391-398.
27. Inoue K, Okugawa K, Kato S, et al. Ocular factors relevant to antiglaucomatous eyedrop-related keratoepitheliopathy. J Glaucoma 2003;12:480-485.
28. Kahook MY, Fechtner RD, Katz LJ, et al. A comparison of active ingredients and preservatives between brand name and generic topical glaucoma medications using liquid chromatographytandem mass spectrometry. Curr Eye Res 2012;37:101-108.
29. Busenbark K, Pahwa R, Hubble J, et al. Double-blind controlled study of methazolamide in the treatment of essential tremor. Neurology 1993;43:1045-1047.
30. Silver LH. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol 2000;44(Suppl 2):S141-S145.
31. Rossi GC, Pasinetti GM, Sandolo F, et al. From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch study. Expert Opin Pharmacother 2011;12:2425-2431.
32. Fung MA. The clinical and histopathologic spectrum of "dermal hypersensitivity reactions," a nonspecific histologic diagnosis that is not very useful in clinical practice, and the concept of a "dermal hypersensitivity reaction pattern." J Am Acad Dermatol 2002;47:898-907.
33. Rossi GC, Pasinetti GM, Scudeller L, et al. Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients. Eur J Ophthalmol 2013;23:296-302.
34. Servat JJ, Bernardino CR. Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue. Drugs Aging 2011;28:267-282.